AMSTERDAM, Netherlands, December 13 /PRNewswire/ --

- Results to be presented at San Antonio Breast Cancer Symposium

Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that an independent international consortium has demonstrated the prognostic power of its MammaPrint(R) breast cancer prognosis test in patients who have 1-3 positive lymph nodes. The data show that MammaPrint(R) can accurately identify a low risk group of lymph node-positive breast cancer patients with an excellent survival, implications that will help doctors to decide the optimal treatment management.

ANTONY, GRENOBLE France, December 13 /PRNewswire/ -- STALLERGENES S.A and Protein'eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens(1).

The partnership is part of the STALLERGENES "Enhanced Allergens" innovation programme for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system.

Protein'eXpert will handle:

- developing processes aimed at optimising the existing production protocol;

LUSTENAU, Austria and DALLAS, Texas, December 13 /PRNewswire/ -- IDENTEC SOLUTIONS recent acquisition of a Wtek, a global leader in providing active RFID solutions in the workplace, sets the stage for IDENTEC SOLUTIONS entry into the growing sector of worker safety and security.

Worker safety and security has long been an ongoing and vital concern for a number of industries. Identifying the location of employees in time sensitive situations can often mean the difference between life and death. By utilizing active RFID, emergency response and deployment in time critical situations is vastly enhanced, thereby offering the employer and employee a greater assurance of overall safety and security.

LONDON, December 13 /PRNewswire/ -- The MS Society has today (13 December) welcomed an unprecedented move by the Medicines and Healthcare products Regulatory Agency (MHRA) to provide potential prescribers of the unlicensed drug Sativex more information to help them in their decision.

Sativex is an oral spray containing a cannabis extract and clinical trials are investigating its efficacy in alleviating symptoms of spasticity and pain in people with multiple sclerosis (MS).

Although currently unlicensed, it is available to people with MS on a named patient basis and around 1,200 people have so far received the drug in the UK.

LONDON, December 13 /PRNewswire/ --

- Your Chance to Hear and Question Sir Ranulph Fiennes on His Living Dangerously Lecture and Learn About the Plight of the Endangered African Lion

LONDON, December 13 /PRNewswire/ --

On Friday 18th January 2008 "An Audience with Sir Ranulph Fiennes and ALERT" will provide people with an exclusive opportunity to hear and question Sir Ranulph Fiennes on his worldwide adventures and endurance feats. As well as discussing quests such as being the first man to visit both the north and south poles by land, Fiennes will also be discussing his work as patron to the African Lion & Environmental Research Trust, ALERT.

BAAR, Switzerland, December 13 /PRNewswire/ --

- Manas Petroleum Corp. (MNAP.OB) (Manas)

"The Albanian Council of Ministers has approved Decision No. 796 regarding the approval of production sharing for exploration, development and production of hydrocarbons on onshore Albania, in Blocks A-B and D-E, between the Ministry of Economy, Trade and Energy, represented by the National Agency of Natural Resources (AKBN) and DWM Petroleum AG." DWM Petroleum AG is 100% subsidiary of Manas.